483
Hetero Drugs Ltd. - Unit 1FDA 483 - Hetero Drugs Ltd. - Unit 1 - May 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Hetero Drugs Ltd. - Unit 1, an API manufacturer in Gummadidala, Telangana, India, was cited with two observations during an FDA inspection. The firm failed to conduct adequate risk assessments and testing for the formation of a known carcinogen in drug products and lacked proper cleaning validation procedures to prevent hazardous drug residue cross-contamination on shared equipment. These issues indicate significant concerns regarding product quality and safety.
Open in Dashboard
ID · 380fe241-c7a9-4330-bbe5-26066c4980b8